Inhibition of angiogenesis and suppression of colorectal cancer metastatic to the liver using the Sleeping Beauty Transposon System

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Belur, Lalitha R ^a,b   Podetz Pedersen, Kelly M ^a,b   Sorenson, Brent S ^b   Hsu, Alice H ^a,b   Parker, Josh B ^b   Carlson, Cathy S ^b   Saltzman, Daniel A ^b   Ramakrishnan, S ^b   McIvor, R Scott ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOSTATIN; ENDOSTATIN; PLASMID DNA; SLEEPING BEAUTY TRANSPOSASE; STATIN AE; TRANSPOSASE; UNCLASSIFIED DRUG; HYBRID PROTEIN; SLEEPING BEAUTY TRANSPOSASE, HUMAN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; FUSION GENE; GENE LOCATION; GENE TARGETING; HISTOPATHOLOGY; LIVER METASTASIS; LIVER WEIGHT; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; SLEEPING BEAUTY TRANSPOSON SYSTEM; TRANSPOSON; TUMOR CELL; TUMOR VASCULARIZATION; ANIMAL; CANCER TRANSPLANTATION; COLORECTAL TUMOR; FEMALE; GENE THERAPY; GENE TRANSFER; GENETICS; KAPLAN MEIER METHOD; LIVER TUMOR; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; REPORTER GENE; TUMOR VOLUME; VASCULARIZATION; XENOGRAFT;

ANIMALIA; MUS;

ANGIOSTATINS; ANIMALS; COLORECTAL NEOPLASMS; ENDOSTATINS; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, REPORTER; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MICE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; RECOMBINANT FUSION PROTEINS; TRANSPLANTATION, HETEROLOGOUS; TRANSPOSASES; TUMOR BURDEN;

EID: 79751526750     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-14     Document Type: Article

References (66)

1. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2009, 1:544-73.
2. Mayo SC, Pawlik TM. Current management of colorectal hepatic metastasis. Expert Rev Gastroenterol Hepatol 2009, 3:131-44. 10.1586/egh.09.8, 19351284.
3. Carpizo DR, D'Angelica M. Liver resection for metastatic colorectal cancer in the presence of extrahepatic disease. Lancet Oncol 2009, 10:801-9. 10.1016/S1470-2045(09)70081-6, 19647200.
4. de Jong MC, Pulitano C, Ribero D, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: An international multi-institutional analysis of 1669 patients. Ann Surg 2009, 250:440-8.
5. Takebayashi Y, Aklyama S, Yamada K, Akiba S, Aikou T. Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma. Cancer 1996, 78:226-31. 10.1002/(SICI)1097-0142(19960715)78:2<226::AID-CNCR6>3.0.CO;2-J, 8673996.
6. Vermeulen PB, Van den Eynden GG, Huget P, et al. Prospective study of intratumoral microvessel density, p53 expression and survival in colorectal cancer. Br J Cancer 1999, 79:316-22. 10.1038/sj.bjc.6690051, 2362196, 9888475.
7. Ivy SP, Wick JY, Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 2009, 6:569-79. 10.1038/nrclinonc.2009.130, 19736552.
8. Segal NH, Saltz LB. Evolving treatment of advanced colon cancer. Annu Rev Med 2009, 60:207-19. 10.1146/annurev.med.60.041807.132435, 19630571.
9. Sobrero A, Ackland S, Clarke S, et al. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology 2009, 77:113-9. 10.1159/000229787, 19628950.
10. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999, 103:159-65. 10.1172/JCI5028, 407882, 9916127.
11. Folkman J. Antiangiogenic gene therapy. Proc Natl Acad Sci USA 1998, 95:9064-6. 10.1073/pnas.95.16.9064, 33874, 9689032.
12. Kong HL, Hecht D, Song W, et al. Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. Hum Gene Ther 1998, 9:823-33. 10.1089/hum.1998.9.6-823, 9581905.
13. Mahasreshti PJ, Kataram M, Wang MH, et al. Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity. Clin Cancer Res 2003, 9:2701-10.
14. Chen CT, Lin J, Li Q, et al. Antiangiogenic gene therapy for cancer via systemic administration of adenoviral vectors expressing secretable endostatin. Hum Gene Ther 2000, 11:1983-96. 10.1089/10430340050143417, 11020798.
15. Feldman AL, Restifo NP, Alexander HR, et al. Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice. Cancer Res 2000, 60:1503-6. 2247479, 10749112.
16. Shi W, Teschendorf C, Muzyczka N, Siemann DW. Adeno-associated virus-mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo. Cancer Gene Ther 2002, 9:513-21. 10.1038/sj.cgt.7700463, 12032662.
17. Gorrin-Rivas MJ, Arii S, Mori A, Kaneda Y, Imamura M. Mouse macrophage metalloelastase gene delivery by HVJ-cationic liposomes in experimental antiangiogenic gene therapy for murine CT-26 colon cancer. Int J Cancer 2001, 93:731-5. 10.1002/ijc.1389, 11477587.
18. Uesato M, Gunji Y, Tomonaga T, et al. Synergistic antitumor effect of antiangiogenic factor genes on colon 26 produced by low-voltage electroporation. Cancer Gene Ther 2004, 11:625-32. 10.1038/sj.cgt.7700740, 15338011.
19. Wen J, Matsumoto K, Taniura N, Tomioka D, Nakamura T. Inhibition of colon cancer growth and metastasis by NK4 gene repetitive delivery in mice. Biochem Biophys Res Commun 2007, 358:117-23. 10.1016/j.bbrc.2007.04.098, 17467663.
20. Wen J, Matsumoto K, Taniura N, Tomioka D, Nakamura T. Hepatic gene expression of NK4, an HGF-antagonist/angiogenesis inhibitor, suppresses liver metastasis and invasive growth of colon cancer in mice. Cancer Gene Ther 2004, 11:419-30. 10.1038/sj.cgt.7700705, 15017381.
21. Ivics Z, Hackett PB, Plasterk RH, Izsvak Z. Molecular reconstruction of sleeping beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell 1997, 91:501-10. 10.1016/S0092-8674(00)80436-5, 9390559.
22. Aronovich EL, Bell JB, Belur LR, et al. Prolonged expression of a lysosomal enzyme in mouse liver after sleeping beauty transposon-mediated gene delivery: Implications for non-viral gene therapy of mucopolysaccharidoses. J Gene Med 2007, 9:403-15. 10.1002/jgm.1028, 1868578, 17407189.
23. Wilber A, Linehan JL, Tian X, et al. Efficient and stable transgene expression in human embryonic stem cells using transposon-mediated gene transfer. Stem Cells 2007, 25:2919-27. 10.1634/stemcells.2007-0026, 17673526.
24. Xue X, Huang X, Nodland SE, et al. Stable gene transfer and expression in cord blood-derived CD34+ hematopoietic stem and progenitor cells by a hyperactive sleeping beauty transposon system. Blood 2009, 114:1319-30. 10.1182/blood-2009-03-210005, 19414858.
25. Yant SR, Meuse L, Chiu W, Ivics Z, Izsvak Z, Kay MA. Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system. Nat Genet 2000, 25:35-41. 10.1038/75568, 10802653.
26. Huang X, Guo H, Kang J, et al. Sleeping beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies. Mol Ther 2008, 16:580-9. 10.1038/sj.mt.6300404, 18227839.
27. Ohlfest JR, Demorest ZL, Motooka Y, et al. Combinatorial antiangiogenic gene therapy by nonviral gene transfer using the sleeping beauty transposon causes tumor regression and improves survival in mice bearing intracranial human glioblastoma. Mol Ther 2005, 12:778-88. 10.1016/j.ymthe.2005.07.689, 16150649.
28. Song J, Kim C, Ochoa ER. Sleeping beauty-mediated suicide gene therapy of hepatocellular carcinoma. Biosci Biotechnol Biochem 2009, 73:165-8. 10.1271/bbb.80581, 19129627.
29. Yokoyama Y, Dhanabal M, Griffioen AW, Sukhatme VP, Ramakrishnan S. Synergy between angiostatin and endostatin: Inhibition of ovarian cancer growth. Cancer Res 2000, 60:2190-6.
30. Raikwar SP, Temm CJ, Raikwar NS, Kao C, Molitoris BA, Gardner TA. Adenoviral vectors expressing human endostatin-angiostatin and soluble Tie2: Enhanced suppression of tumor growth and antiangiogenic effects in a prostate tumor model. Mol Ther 2005, 12:1091-100. 10.1016/j.ymthe.2005.07.690, 2763308, 16169279.
31. Ponnazhagan S, Mahendra G, Kumar S, et al. Adeno-associated virus 2-mediated antiangiogenic cancer gene therapy: Long-term efficacy of a vector encoding angiostatin and endostatin over vectors encoding a single factor. Cancer Res 2004, 64:1781-7. 10.1158/0008-5472.CAN-03-1786, 14996740.
32. Scappaticci FA, Smith R, Pathak A, et al. Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice. Mol Ther 2001, 3:186-96. 10.1006/mthe.2000.0243, 11237675.
33. Cui Z, Geurts AM, Liu G, Kaufman CD, Hackett PB. Structure-function analysis of the inverted terminal repeats of the sleeping beauty transposon. J Mol Biol 2002, 318:1221-35. 10.1016/S0022-2836(02)00237-1, 12083513.
34. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006, 3:24-40. 10.1038/ncponc0403, 16407877.
35. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005, 65:671-80.
36. Chase JL. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer. Pharmacotherapy 2008, 28(11 Pt 2):23S-30S. 10.1592/phco.28.11-supp.23S, 18980549.
37. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9:669-76. 10.1038/nm0603-669, 12778165.
38. Ellis LM, Takahashi Y, Liu W, Shaheen RM. Vascular endothelial growth factor in human colon cancer: Biology and therapeutic implications. Oncologist 2000, 5(Suppl 1):11-5. 10.1634/theoncologist.5-suppl_1-11, 10804085.
39. Ellis LM, Hicklin DJ. VEGF-targeted therapy: Mechanisms of anti-tumour activity. Nat Rev Cancer 2008, 8:579-91. 10.1038/nrc2403, 18596824.
40. Li X, Liu YH, Lee SJ, Gardner TA, Jeng MH, Kao C. Prostate-restricted replicative adenovirus expressing human endostatin-angiostatin fusion gene exhibiting dramatic antitumor efficacy. Clin Cancer Res 2008, 14:291-9. 10.1158/1078-0432.CCR-07-0867, 18172281.
41. Balciunas D, Ekker SC. Trapping fish genes with transposons. Zebrafish 2005, 1:335-41. 10.1089/zeb.2005.1.335, 18248211.
42. Dupuy AJ, Akagi K, Largaespada DA, Copeland NG, Jenkins NA. Mammalian mutagenesis using a highly mobile somatic sleeping beauty transposon system. Nature 2005, 436:221-6. 10.1038/nature03691, 16015321.
43. Belur LR, Frandsen JL, Dupuy AJ, et al. Gene insertion and long-term expression in lung mediated by the sleeping beauty transposon system. Mol Ther 2003, 8:501-7. 10.1016/S1525-0016(03)00211-9, 12946324.
44. Aronovich EL, Bell JB, Khan SA, et al. Systemic correction of storage disease in MPS I NOD/SCID mice using the sleeping beauty transposon system. Mol Ther 2009, 17:1136-44. 10.1038/mt.2009.87, 2835207, 19384290.
45. Kren BT, Unger GM, Sjeklocha L, et al. Nanocapsule-delivered sleeping beauty mediates therapeutic factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice. J Clin Invest 2009, 119:2086-99. 2701853, 19509468.
46. Score PR, Belur LR, Frandsen JL, et al. Sleeping beauty-mediated transposition and long-term expression in vivo: Use of the LoxP/Cre recombinase system to distinguish transposition-specific expression. Mol Ther 2006, 13:617-24. 10.1016/j.ymthe.2005.10.015, 16356773.
47. Wilber A, Wangensteen KJ, Chen Y. Messenger RNA as a source of transposase for sleeping beauty transposon-mediated correction of hereditary tyrosinemia type I. Mol Ther 2007, 15:1280-1287. 10.1038/sj.mt.6300160, 17440442.
48. Montini E, Held PK, Noll M, et al. In vivo correction of murine tyrosinemia type I by DNA-mediated transposition. Mol Ther 2002, 6:759-69. 10.1006/mthe.2002.0812, 12498772.
49. Liu G, Aronovich EL, Cui Z, et al. Excision of Sleeping Beauty transposons: parameters and applications to gene therapy. J Gene Med 2004, 6:574-83. 10.1002/jgm.486, 1865527, 15133768.
50. Bell JB, Aronovich EL, Schreifels JM, et al. Duration of Expression and Activity of Sleeping Beauty Transposase in mouse liver following hydrodynamic DNA delivery. Mol Ther 2010, 18:1796-1802. 10.1038/mt.2010.152, 20628359.
51. Martin HA, Zhang W, Müther N, et al. Hyperactive Sleeping Beauty Transposase Enables Persistent Phenotypic Correction in Mice and a Canine Model for Hemophilia B. Mol Ther 2010, 18:1896-1906. 10.1038/mt.2010.169, 20717103.
52. Ohlfest JR, Frandsen JL, Fritz S, et al. Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system. Blood 2005, 105:2691-8. 10.1182/blood-2004-09-3496, 15576475.
53. Wu A, Oh S, Ericson K, et al. Transposon-based interferon gamma gene transfer overcomes limitations of episomal plasmid for immunogene therapy of glioblastoma. Cancer Gene Ther 2007, 14:550-60. 10.1038/sj.cgt.7701045, 17415381.
54. Eastman SJ, Baskin KM, Hodges BL, et al. Development of catheter-based procedures for transducing the isolated rabbit liver with plasmid DNA. Hum Gene Ther 2002, 13:2065-77. 10.1089/10430340260395910, 12490001.
55. Yoshino H, Hashizume K, Kobayashi E. Naked plasmid DNA transfer to the porcine liver using rapid injection with large volume. Gene Ther 2006, 13:1696-1702. 10.1038/sj.gt.3302833, 16871229.
56. Fabre JW, Grehan A, Whitehorne M, et al. Hydrodynamic gene delivery to the pig liver via an isolated segment of the inferior vena cava. Gene Ther 2008, 15:452-62. 10.1038/sj.gt.3303079, 18004400.
57. Hackett PB, Urness M, Bell JB, et al. Long-term gene expression after hydrodynamic delivery of Sleeping Beauty transposons to canine liver using balloon catheters. Mol Ther 2010, 18:325.
58. Suda T, Suda K, Liu D. Computer-assisted hydrodynamic gene delivery. Mol Ther 2008, 16:1098-104. 10.1038/mt.2008.66, 18398428.
59. Kamimura K, Zhang G, Liu D. Image-guided, intravascular hydrodynamic gene delivery to skeletal muscle in pigs. Mol Ther 2010, 18:93-100. 10.1038/mt.2009.206, 2805042,2805042, 19738603.
60. Lutzko C, Kruth S, Abrams-Ogg AC, et al. Genetically corrected autologous stem cells engraft, but host immune responses limit their utility in canine alpha-L-iduronidase deficiency. Blood 1999, 15:1895-905.
61. Schowalter DB, Himeda CL, Winther BL, et al. Implication of interfering antibody formation and apoptosis as two different mechanisms leading to variable duration of adenovirus-mediated transgene expression in immune-competent mice. J Virol 1999, 73:4755-66. 112518, 10233936.
62. Hodges BL, Taylor KM, Joseph MF, et al. Long-term transgene expression from plasmid DNA gene therapy vectors is negatively affected by CpG dinucleotides. Mol Ther 2004, 10:269-78. 10.1016/j.ymthe.2004.04.018, 15294174.
63. Multhaup MM, Karlen AD, Swanson DL, et al. Cytotoxicity associated with artemis over-expression after lentiviral vector mediated gene transfer. Hum Gene Ther 2010, 21(7):865-75. 10.1089/hum.2009.162, 20163250.
64. Lafreniere R, Rosenberg SA. A novel approach to the generation and identification of experimental hepatic metastases in a murine model. J Natl Cancer Inst 1986, 76:309-322.
65. Belur LR, McIvor RS, Wilber A. Liver-directed gene therapy using the sleeping beauty transposon system. Methods Mol Biol 2008, 434:267-76. full_text, 18470650.
66. Wilber A, Frandsen JL, Wangensteen KJ, et al. Dynamic gene expression after systemic delivery of plasmid DNA as determined by in vivo bioluminescence imaging. Hum Gene Ther 2005, 16:1325-32. 10.1089/hum.2005.16.1325, 16259566.